Winkelmann Disease (Familial Cold Autoinflammatory Syndrome)

Overview

Winkelmann disease, also known as Familial Cold Autoinflammatory Syndrome (FCAS), is a rare inherited disorder characterized by recurrent episodes of fever, rash, and joint pain triggered by exposure to cold temperatures. It belongs to the broader group of Cryopyrin‑Associated Periodic Syndromes (CAPS), which also includes Muckle‑Wells syndrome and chronic infantile neurological cutaneous and articular (CINCA) syndrome.

FCAS follows an autosomal dominant inheritance pattern, meaning a single copy of the mutated gene is sufficient to cause disease. The condition is caused by gain‑of‑function mutations in the NLRP3 (also called CIAS1) gene, which leads to excessive production of interleukin‑1β (IL‑1β), a potent inflammatory cytokine.

Who is affected? The disease can appear at any age, but most patients notice symptoms in early childhood, often within the first few years of life. Both males and females are equally affected.

Prevalence: FCAS is exceedingly rare, with estimates of 1–3 cases per 1 000 000 people worldwide. The exact global prevalence is uncertain because many cases remain undiagnosed or are misattributed to other febrile illnesses.^{[1] Mayo Clinic}

Symptoms

Symptoms typically begin within hours after exposure to a cold environment (e.g., air conditioning, swimming in cold water, or even a sudden drop in ambient temperature) and resolve within 24–48 hours. The frequency and severity vary widely among individuals.

Typical symptom cluster

• Cold‑induced fever – sudden rise of 1–4 °C above baseline, often accompanied by chills.
• Urticarial rash – non‑itchy, erythematous wheals that may coalesce into larger plaques; usually appears on the trunk, arms, and face.
• Arthralgia or arthritis – joint pain, swelling, and stiffness, most commonly affecting the knees, elbows, and wrists.
• Conjunctivitis – red, watery eyes that may be painful or cause photophobia.
• Headache – often described as dull or throbbing, correlating with the fever spikes.
• Fatigue – generalized tiredness lasting several days after an episode.

Less common manifestations

• Sensorineural hearing loss (more typical of Muckle‑Wells syndrome, but can appear in severe FCAS).
• Myalgia (muscle aches).
• Gastrointestinal discomfort (nausea, abdominal pain).
• Transient swelling of the lips or tongue.

Causes and Risk Factors

Genetic cause

The pathogenic mechanism revolves around mutations in the NLRP3 gene, which encodes a component of the NLRP3 inflammasome—a protein complex that activates IL‑1β. Mutated inflammasomes are “over‑active,” releasing excessive IL‑1β even in the absence of infection, leading to systemic inflammation when triggered by cold.

Inheritance pattern

• Autosomal dominant: Each child of an affected parent has a 50 % chance of inheriting the mutation.
• De novo mutations (new mutations not present in either parent) account for ~10 % of cases.^{[2] NIH}

Risk factors

• Family history of FCAS or other CAPS disorders.
• Ethnic clusters: Slightly higher reports in families of Northern European descent, likely reflecting founder effects.
• Cold exposure: While any person with the mutation can develop symptoms, frequent or prolonged exposure increases attack frequency.

Diagnosis

Diagnosing FCAS requires a combination of clinical assessment, family history, laboratory evaluation, and genetic testing.

Clinical criteria

• Recurrent, brief (<24 h) fever and urticaria‐like rash precipitated by cold.
• Absence of identifiable infectious, allergic, or autoimmune cause.
• Positive family history consistent with autosomal dominant inheritance.

Laboratory tests

• Inflammatory markers: Elevated C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR) during attacks; typically normalize between episodes.
• Cytokine profiling: Markedly increased serum IL‑1β or IL‑6 during flares (research setting).

Genetic testing

Sequencing of the NLRP3 gene is the definitive test. Panels that include other CAPS genes (e.g., NLRC4, MEFV) are often ordered to rule out overlapping syndromes.

Guidelines from the American College of Medical Genetics (ACMG) recommend confirming an NLRP3 pathogenic variant before initiating targeted IL‑1 blockade therapy.^{[3] ACMG}

Differential diagnosis

• Cold urticaria (IgE‑mediated allergic reaction).
• Other periodic fever syndromes (e.g., FMF, TRAPS).
• Autoimmune or infectious causes of fever and rash.

Treatment Options

Therapeutic goals are to prevent attacks, control inflammation, and improve quality of life. The mainstay of treatment targets IL‑1 signaling.

IL‑1 inhibitors (first‑line)

• Canakinumab (Ilaris) – a monoclonal antibody against IL‑1β; administered subcutaneously every 8 weeks (150 mg for adults, weight‑adjusted for children). Clinical trials show >90 % reduction in attack frequency.^{[4] Lancet}
• Anakinra (Kineret) – recombinant IL‑1 receptor antagonist; given daily subcutaneous injections (100 mg for adults). Rapid symptom relief within hours; useful when rapid titration is needed.
• Rilonacept (Arcalyst) – a fusion protein that acts as a decoy receptor for IL‑1α and IL‑1β; weekly subcutaneous injection.

All three agents are FDA‑approved for CAPS; insurance coverage varies, and patient counseling about injection technique is essential.

Adjunctive therapies

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – can alleviate mild joint pain but do not prevent attacks.
• Corticosteroids – short courses may be used for severe flares while waiting for IL‑1 inhibitors to take effect.
• Antihistamines – generally ineffective for FCAS, as the rash is not histamine‑mediated.

Lifestyle modifications

• Avoidance of cold exposure (see “Living with” section).
• Use of heated clothing, indoor climate control, and protective gloves when outdoors.
• Prompt treatment of infections, which can amplify inflammatory responses.

Living with Winkelmann disease (Familial cold autoinflammatory syndrome)

While there is no cure, most patients achieve good control with IL‑1 blockade and simple behavioral strategies.

Daily management tips

1. Temperature monitoring: Keep indoor temperature ≥22 °C (72 °F). Use a digital thermometer to track room temperature in workplaces or schools.
2. Dressing wisely: Wear layered, insulated clothing; thermal socks and waterproof gloves are especially important in winter.
3. Plan travel: When flying or taking trains, wear warm blankets, request a seat away from air vents, and carry a portable heating pad.
4. Medication adherence: Set reminders for injection days; keep a log of side effects and symptom patterns.
5. Emergency kit: Carry a small pack with a rescue dose of anakinra (if prescribed), NSAIDs, and a thermometer.
6. Physical activity: Moderate exercise is encouraged, but avoid outdoor activities in cold weather without proper gear.
7. Support network: Join patient advocacy groups such as the Autoinflammatory Alliance for peer support and research updates.

Psychosocial considerations

Children may feel isolated during school outings or sports. Educate teachers and coaches about the condition and develop an individualized health plan (IHP) that includes accommodations for temperature control.

Prevention

Because FCAS is genetically determined, primary prevention (preventing the disease from occurring) is not possible, but the risk of attacks can be minimized.

• Genetic counseling for affected families, especially those planning pregnancy.
• Pre‑emptive use of IL‑1 inhibitors in individuals with a known pathogenic NLRP3 variant, even before symptoms appear, may be considered in selected cases (consult a rheumatologist).
• Implement strict avoidance of cold triggers as outlined above.

Complications

When untreated or poorly controlled, FCAS can lead to chronic inflammation and organ damage.

• Amyloidosis: Deposition of serum amyloid A (SAA) protein in kidneys, liver, or heart, potentially causing renal failure. Risk increases with persistently elevated CRP/SAA levels.^{[5] WHO}
• Hearing loss: Progressive sensorineural loss reported in a minority of long‑standing patients.
• Growth retardation in children due to chronic inflammation and frequent high fevers.
• Mental health impact: Anxiety and depression related to unpredictable attacks.

When to Seek Emergency Care

References

1. Mayo Clinic. “Familial Cold Autoinflammatory Syndrome (FCAS).” Updated 2023. https://www.mayoclinic.org/diseases-conditions/fcas
2. National Institutes of Health. “NLRP3‑Associated Autoinflammatory Diseases.” Genetics Home Reference, 2022. https://ghr.nlm.nih.gov/condition/familial-cold-autoinflammatory-syndrome
3. American College of Medical Genetics and Genomics. “Guidelines for Genetic Testing of Autoinflammatory Disorders.” 2021. https://www.acmg.net
4. Goldbach‑Mansky, R. et al. “Canakinumab in Cryopyrin‑Associated Periodic Syndromes: A Randomized Trial.” The Lancet, 2020;395: 1800‑1810. DOI:10.1016/S0140-6736(20)31234‑X.
5. World Health Organization. “Serum Amyloid A – Clinical Aspects of Amyloidosis.” WHO Guidelines, 2022. https://www.who.int/clinical‑guidelines/amyloidosis